NCT07138846View on ClinicalTrials.gov

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

MRG004A plus best supportive care

MRG004A will be administrated as specified in the protocol.

DRUG

Placebo plus best supportive care

Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY